Matthew Lawrence

Dr. Matthew Lawrence is an Assistant Professor (Adjunct Primary) in Comparative Medicine at Yale University's Yale School of Medicine. He co-founded RxGen, a preclinical research organization focused on pharmakokinetics and emerging therapeutics. His work bridges basic science and translational medicine, emphasizing drug development and ocular/vascular biology.

Education:
- MD, Yale School of Medicine (1999)
- PhD, Stanford University (1995)
- BA, Harvard College (1991)

Research Interests: Lawrence's research focuses on pharmacokinetic modeling in primates, ocular and vascular biology, and neuroprotective gene therapies. Key areas include retinal neoangiogenesis, drug-drug interactions in preclinical models, and optimizing therapeutic delivery for ophthalmic and neurodegenerative conditions.

Articles Overview: His recent work (2025) highlights anti-angiogenic therapies for retinal diseases, while earlier studies (2000–2009) established primate models for drug evaluation and explored neuroprotective gene therapies.

Labs/Teams: RxGen serves as a core platform for his translational research, specializing in preclinical drug assessment and vascular pharmacology.